TNFRSF17 and Miyoshi myopathy: Current BsAbs under investigation target a variety of MM-specific antigens, including B cell maturation antigen (BCMA), a target for which agents with different mechanisms of action are available, such as antibody-drug conjugates (ADC) and chimeric antigen receptor (CAR) T-cell therapies.